ABVX:EPA
Abivax SA
76,10 €
arrow_downward
-0,72%(-0,55) 1D
19-ноя., 17:35:26 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
77,35 €
High
79,30 €
Low
75,85 €
Mkt. cap
6,75 млд
Avg. vol.
110,41 миң
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
77,35 €
High
79,30 €
Low
75,85 €
Mkt. cap
6,75 млд
Avg. vol.
110,41 миң
Volume
0,00
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
FOREX.com
·
20 мүнөт мурун
S&P 500 Analysis: SPX Is Going Through One of Its Most Difficult Periods of 2026
FXStreet
·
8 саат мурун
Dow Jones Industrial Average falls over 1,000 points as Anthropic IPO dominates
Traders Union
·
7 саат мурун
S&P 500 sees $2 trillion swing and 8.5 percent drop, Peter Tuchman notes
BigGo Finance
·
5 саат мурун
Chip ETF Eyes Unprecedented Fourth Straight Year of Beating the S&P 500
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013-ж., 4-дек.
Headquarters-
SectorHealth Care
IndustryPharmaceutical industry
Websiteabivax.com